<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784016</url>
  </required_header>
  <id_info>
    <org_study_id>SmokingPETD2-3fMRI</org_study_id>
    <secondary_id>R21DA031925-01A1</secondary_id>
    <nct_id>NCT01784016</nct_id>
  </id_info>
  <brief_title>Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers</brief_title>
  <official_title>Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <brief_summary>
    <textblock>
      This trial aims to determine whether dopamine D3 receptors are elevated in smokers versus
      nonsmokers and whether correlations exist between D3 receptor binding potential (BP) and
      functional MRI (fMRI) reactivity to smoking cues, which has been associated with smoking
      relapse vulnerability.

      Neuroimaging measures of D3 BP and smoking cue fMRI reactivity will be collected concurrently
      in otherwise healthy nicotine-dependent smokers and age-matched nonsmokers using a 3 Tesla
      MRI scanner configured to conduct fMRI and Positron Emission Tomography (PET).

      We will measure D3 receptor BP using radiolabeled [11C]-(+)-PHNO, which has a relatively
      higher affinity for D3 versus D2 receptors.

      We hypothesize that D3 BP will be elevated in smokers versus nonsmokers and that in smokers,
      there will be a positive correlation between smoking cue fMRI reactivity and D3 BP.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Technical complications.
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine D3 Receptor Binding Potential Difference Between Smokers and Nonsmokers</measure>
    <time_frame>March 2014</time_frame>
    <description>We will determine whether dopamine D3 receptor binding potential, a dimensionless number which represents the relative concentration of dopamine D3 receptors available for binding, is elevated in smokers versus nonsmoking controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking Cue fMRI Reactivity Association with Dopamine D3 Receptor Binding Potential</measure>
    <time_frame>March 2014</time_frame>
    <description>In smokers, we will determine whether an association exists between smoking cue fMRI reactivity intensity (beta weight) and dopamine D3 receptor binding potential, a relationship between receptor (D3) density and dopamine occupancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Smoking Cue Reactivity</condition>
  <condition>Relapse to Smoking</condition>
  <arm_group>
    <arm_group_label>Healthy Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Nonsmokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy nonsmoking controls aged 18-50 reporting consumption of &lt;100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of &lt; 9 ppm at screening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[11C]-PHNO</intervention_name>
    <description>[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.</description>
    <arm_group_label>Healthy Smokers</arm_group_label>
    <arm_group_label>Healthy Nonsmokers</arm_group_label>
    <other_name>11C-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  competent to provide written informed consent

          -  Smokers: self-report of smoking 15 or more cigarettes/day for the past year,
             self-report of smoking first cigarette of the day within 30 minutes of awakening,
             meets DSM-IV criteria for Nicotine Dependence, provides expired breath carbon monoxide
             reading of &gt; 10 ppm at enrollment

          -  Nonsmokers: self-report of consuming &lt;100 cigarettes in their lifetime, none in the
             last 6 months, provides expired breath carbon monoxide reading of &lt; 9 ppm at
             enrollment

          -  Women of childbearing potential: negative STAT serum beta-human chorionic
             gonadotrophin pregnancy test before scanning

        Exclusion Criteria:

          -  pregnant or able to become pregnant and not willing to undergo blood pregnancy test

          -  unstable medical illness with likely hospitalization for treatment within 6 months

          -  life-threatening arrhythmia, cerebro-vascular or cardiovascular event within 6 months
             of enrollment; liver function tests elevated over 2.5x normal; CNS tumor or seizure
             disorder

          -  users of other tobacco- or nicotine-containing products (gum, patches, e-cigarettes)

          -  lifetime history of DSM-IV bulimia, organic mental disorder, brain injury or psychotic
             disorder

          -  6 month history of non-nicotine substance use disorder or major depression

          -  history of multiple adverse drug reactions

          -  current use of excluded concomitant medications (smoking cessation medications)

          -  known history of allergic reaction to the PET ligand [11C]-PHNO, its components, or
             any medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc J. Kaufman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry. 2010 Apr 15;67(8):722-9. doi: 10.1016/j.biopsych.2009.12.034. Epub 2010 Feb 20. Erratum in: Biol Psychiatry. 2010 May 15;67(10):1002.</citation>
    <PMID>20172508</PMID>
  </reference>
  <reference>
    <citation>Le Foll B, Diaz J, Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse. 2003 Mar;47(3):176-83.</citation>
    <PMID>12494400</PMID>
  </reference>
  <reference>
    <citation>Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry. 2010 Aug 15;68(4):392-9. doi: 10.1016/j.biopsych.2010.04.038.</citation>
    <PMID>20599188</PMID>
  </reference>
  <reference>
    <citation>Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage. 2011 Jan 1;54(1):264-77. doi: 10.1016/j.neuroimage.2010.06.044. Epub 2010 Jun 30.</citation>
    <PMID>20600980</PMID>
  </reference>
  <reference>
    <citation>Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005 Jun 16;48(12):4153-60.</citation>
    <PMID>15943487</PMID>
  </reference>
  <reference>
    <citation>Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol. 2006 Oct;9(5):585-602. Epub 2006 Aug 31.</citation>
    <PMID>16942635</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Marc J. Kaufman</investigator_full_name>
    <investigator_title>Director, Translational Imaging Laboratory, McLean Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

